Current Market Access to Avsola, Inflectra and Remicade

While biosimilars Avsola and Inflectra are picking up ground, Remicade is still more advantaged, holding covered or better status for 61% of all insured lives.

NOTE: Access that requires prior authorization and/or step therapy is represented by the abbreviation (PA/ST). 274.0 million lives are covered under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 7/12/21.

AIS Health Staff

AIS Health Staff

Related Posts

bills-and-pills
May 19

Various Components Play Important Role in Companies’ Definition, Demonstration of Drugs’ Value

Read More
abdominal-pain-patient-with-a-doctor
May 19

FDA’s Rinvoq Approval Brings Another Ulcerative Colitis Option

Read More
pills-and-dollars
May 19

Study: With High Prices, Rebate Revenue Is Growing for PBMs

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today